Investment Rating - The report maintains a "Buy" rating for the company [4] Core Viewpoints - The company has launched a significant new product, Ruby Oil, which is expected to expand its health supplement business [2] - The self-owned brands, Zhanjia and Feicui, are driving growth with Zhanjia projected to achieve a revenue of 501 million yuan in 2024, a year-on-year increase of 90.28% [2] - The company's profitability is expected to improve due to the growth of its self-owned brands, with gross margins and net profit margins increasing in 2024 [3] - The brand management business is showing strong growth, with revenue expected to reach 501 million yuan in 2024, a year-on-year increase of 212.24% [3] - The company has adjusted its net profit forecasts for 2025 and 2026 upwards due to better-than-expected growth in self-owned brands, with a new forecast for 2027 net profit of 300 million yuan [4] Financial Projections - Total revenue is projected to grow from 1,366 million yuan in 2023 to 4,762 million yuan in 2027, with a compound annual growth rate (CAGR) of approximately 31.04% [1] - The net profit attributable to the parent company is expected to increase from 54.29 million yuan in 2023 to 302.92 million yuan in 2027, reflecting a CAGR of approximately 30.37% [1] - The earnings per share (EPS) is forecasted to rise from 0.33 yuan in 2023 to 1.85 yuan in 2027 [1]

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Insights - The company has launched a significant new product, Ruby Oil, which is expected to expand its health supplement business [2] - The self-owned brands, Zhanjia and Feicui, are driving growth with Zhanjia projected to achieve a revenue of 5.01 billion yuan in 2024, a year-on-year increase of 90.28% [2] - The company's profitability is expected to improve due to the growth of its self-owned brands, with gross margins and net profit margins increasing in 2024 [3] - The brand management business is showing strong growth, with revenue expected to reach 5.01 billion yuan in 2024, a year-on-year increase of 212.24% [3] - The company has adjusted its net profit forecasts for 2025 and 2026 upwards due to better-than-expected growth in self-owned brands [4] Financial Projections - Total revenue is projected to grow from 1.37 billion yuan in 2023 to 4.76 billion yuan in 2027, with a compound annual growth rate (CAGR) of 31.04% [1] - Net profit attributable to the parent company is expected to increase from 54.29 million yuan in 2023 to 302.92 million yuan in 2027, reflecting a CAGR of 30.37% [1] - The earnings per share (EPS) is forecasted to rise from 0.33 yuan in 2023 to 1.85 yuan in 2027 [1]

Group 1 - The core viewpoint of the articles highlights the successful launch of new products by the companies, specifically the introduction of the "Ruby Oil" by Feicui, which is a high-end fish oil designed for women, featuring unique ingredients that enhance absorption and provide various health benefits [1] - Feicui's new brand is expected to leverage the unique Ruby Oil ingredient, which has a differentiated structure, leading to a high certainty of success in the health supplement market [1] - The company has established a strong operational experience in health supplements, which, combined with the exclusive new ingredient, positions the new brand for high certainty in its market performance [1] Group 2 - Zhenjia has experienced significant growth in sales through dual channels, with a 547% year-on-year increase in sales on Douyin as of May 18, indicating a strong market presence and potential for further acceleration during promotional events [1] - On Tmall, Zhenjia ranked among the top 10 in the home cleaning category during the 618 pre-sale event, showcasing a 7-position improvement compared to the previous year, reflecting its growing popularity [1] - The company is positioned to capitalize on the consumer upgrade trend in the home cleaning sector, with a focus on high-end fragrance products that meet evolving consumer demands [1][2] Group 3 - The investment recommendation emphasizes the differentiated positioning of Zhenjia and Feicui in the high-end fragrance home cleaning and oral beauty markets, suggesting a strong growth trajectory driven by new consumer scenarios and multiple product offerings [2] - The unique Ruby Oil is anticipated to be a significant growth driver for Feicui, reinforcing the high certainty of success in the new brand development [2] - The companies are expected to focus on core female demographics and explore niche market demands, aiming to create a "small but beautiful" brand matrix that aligns with consumer trends [2]

Group 1 - The concept of ergothioneine has gained significant attention in the A-share market, with stocks related to this concept experiencing strong price increases [2][3] - Key stocks in the ergothioneine sector include Tuoxin Pharmaceutical and Chuaning Biological, both of which reached their daily limit up, while other companies like Bawei Co., Xianle Health, and Huaxi Biological also saw gains [2][3] - The chairman of Kelun Pharmaceutical, Liu Gexin, has endorsed the company's anti-aging product "ergothioneine capsules," claiming to have used the product for three years, which has contributed to the product's popularity [2][3] Group 2 - Kelun Pharmaceutical reported a revenue of 4.39 billion yuan in Q1, a year-on-year decline of 29.42%, with a net profit of 584 million yuan, down 43.07% [2][4] - The decline in revenue and profit is attributed to high base effects from the previous year and the impact of centralized procurement on the infusion business [2][4] - The company aims to establish a new subsidiary, Kelun Yongnian, to focus on the sales of ergothioneine products, indicating a strategic shift towards the health industry [3][4] Group 3 - There are 14 stocks in the A-share market related to ergothioneine, with Huadong Medicine, Kelun Pharmaceutical, and Chuaning Biological having the largest market capitalizations [4] - The average stock price increase for ergothioneine-related stocks this year is 19.16%, with Ruoyuchen leading with a 104.62% increase [4] - Half of the ergothioneine concept stocks reported positive net profits in Q1, with companies like Changshan Pharmaceutical turning losses into profits [4] Group 4 - There was a significant net inflow of capital into ergothioneine concept stocks today, with Chuaning Biological, Jindawei, and Kelun Pharmaceutical seeing the highest net inflows of 563 million yuan, 153 million yuan, and 129 million yuan respectively [5]

Group 1 - The pet economy concept rose by 1.98%, ranking third among concept sectors, with 54 stocks increasing in value, including major gainers like Meino Biological and Jieya Co., which hit the 20% limit up [1][2] - Notable stocks with significant increases include Xianle Health, Huisheng Biological, and Yiyuan Magic Yam, which rose by 13.41%, 10.50%, and 9.10% respectively [1] - The leading decliners in the sector were Zhiou Technology, Qingmu Technology, and Yingstone Network, which fell by 4.64%, 4.42%, and 2.73% respectively [1] Group 2 - The pet economy sector saw a net inflow of 236 million yuan, with 48 stocks receiving net inflows, and 7 stocks attracting over 30 million yuan each [2] - The top stock for net inflow was Yong'an Pharmaceutical, with a net inflow of 68.36 million yuan, followed by Jieya Co., Ruoyuchen, and Meino Biological with net inflows of 48.24 million yuan, 46.14 million yuan, and 45.47 million yuan respectively [2][3] Group 3 - In terms of net inflow ratios, Jieya Co., Jiabiyou, and Meino Biological led with net inflow rates of 27.98%, 13.31%, and 11.04% respectively [3] - The pet economy sector's inflow ranking included stocks like Yong'an Pharmaceutical, Jieya Co., Ruoyuchen, and Meino Biological, all showing strong performance in terms of trading volume and turnover rates [3][4]

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 广州若羽臣科技股份有限公司（以下简称"公司""若羽臣"）于2025年2 月26日披露了《关于持股5%以上股东减持股份预披露公告》（公告编号：2025-015）， 朗姿股份有限公司（以下简称"朗姿股份"）计划合计减持若羽臣股份数量不超 过4,768,071股，不超过若羽臣总股本的3%。其中，通过集中竞价方式减持不超 过1,589,357股，不超过若羽臣总股本的1%，且在任意连续90个自然日内减持股 份的总数不超过若羽臣总股本的1%；通过大宗交易方式减持不超过3,178,714股， 不超过若羽臣总股本的2%，且任意连续90个自然日内减持股份的总数不超过若羽 臣总股本的2%。（总股本以公司当前总股本164,030,506股剔除公司截至本公告 披露日已披露回购结果的2024年第三期股份回购和2024年第四期股份回购的回 购专用证券账户持有的5,094,800股后的股份数量158,935,706 股为计算依据， 下同。） 2025年3月22日，公司于巨潮资讯网（http://www.cninfo.com.cn）披露了 《关于持股5%以上股东权益变动后持 ...

智通财经5月15日电，大消费概念持续走强，日化、保健品、宠物经济等新消费方向领涨，午后华业香 料、百洋股份涨停，此前金达威、西王食品、交大昂立、若羽臣涨停，青松股份、中草香料、仙乐健 康、丸美生物等涨幅靠前。消息面上，机构指出，当前，国内新消费企业增长强劲，在审美、精神满足 上的升级持续存在，以潮玩、IP文化、宠物等为主的"情感"消费、"体验"消费景气度更是持续上升。 大消费概念持续走高 华业香料等多股涨停 ...

证券代码：003010 证券简称：若羽臣 公告编号：2025-043 广州若羽臣科技股份有限公司 关于持股 5%以上股东权益变动后持股比例触及 1% 整数倍的公告 持股 5%以上的股东朗姿股份有限公司保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 广州若羽臣科技股份有限公司（以下简称"公司""若羽臣"）于2025年2 月26日披露了《关于持股5%以上股东减持股份预披露公告》 （公告编号：2025-015）， A股 2,265,500 1.43 | 合 计 | 2,265,500 | | 1.43 | | | --- | --- | --- | --- | --- | | | 通过证券交易所的集中交易 | | ? | | | 本次权益变动方式（可 | | | | | | | 通过证券交易所的大宗交易 | | ? | | | 多选） | | | | | | 其他 | | | □（请注明） | | | 股份性质 | 本次变动前持有股份 | | | 本次变动后持有股份 | | | 占公司 | | | | | | 剔 ...

公司于2025年3月22日在巨潮资讯网（http://www.cninfo.com.cn）披露了 《关于持股5%以上股东权益变动后持股比例触及5%整数倍的提示性公告》（公告 编号：2025-021）、《简式权益变动报告书》，截至2025年3月20日，朗姿股份 减持公司股份476,800股，占公司剔除回购专用账户股份后的总股本比例0.3%， 本次权益变动后，朗姿股份持有公司股份15,893,540股，占公司剔除回购专用账 户股份后的总股本比例10.00%。 证券代码：003010 证券简称：若羽臣 公告编号：2025-043 广州若羽臣科技股份有限公司 关于持股 5%以上股东权益变动后持股比例触及 1% 整数倍的公告 持股 5%以上的股东朗姿股份有限公司保证向本公司提供的信息内容真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 广州若羽臣科技股份有限公司（以下简称"公司""若羽臣"）于2025年2 月26日披露了《关于持股5%以上股东减持股份预披露公告》（公告编号：2025-015）， 朗姿股份有限公司（以下简称"朗姿股份"）计划合计减 ...

证券代码：003010 证券简称：若羽臣 投资者关系活动记录表 | 编号：2025-002 | | --- | | | ☐特定对象调研 ☐分析师会议 | | --- | --- | | | ☐媒体采访 业绩说明会 | | 投资者关系活动类别 | ☐新闻发布会 ☐路演活动 | | | ☐现场参观 | | | ☐其他（请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 线上参与公司2024年度业绩说明会的投资者 | | 时间 | 2025年5月13日 15:00-16:30 | | 地点 | 价值在线（https://www.ir-online.cn/）网络互动 | | | 董事长、总经理 王玉 | | 上市公司接待人员姓名 | 董事、副总经理、董事会秘书、财务总监 罗志青 | | | 独立董事 张春艳 | | | 1.贵司斐萃的毛利率是多少 | | | 答:感谢您对公司业务的关注，该业务的毛利率受多种因素综 | | 投资者关系活动 | 合影响，且处于动态变化之中。公司一直致力于优化成本与提升营 | | 主要内容介绍 | 收，努力保持业务的盈利能力和可持续发展，具体数据可持续关注 | | | 公司后续 ...